Related Experiment Video
Updated: May 8, 2025
04:50
An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
147
The First Triple Agonist for Antiobesity: Retatrutide
Lauren Tetelbaun1, Jamie A Mullally2, William H Frishman1,2
1From the School of Medicine, New York Medical College, Valhalla, NY.
Cardiology in Review
|December 26, 2024
Summary
Retatrutide, a novel triple agonist, shows superior weight loss in clinical trials for obesity. This new medication offers significant potential for managing overweight and obesity beyond traditional lifestyle changes.
Area of Science:
- Pharmacology
- Endocrinology
- Metabolic Diseases
Background:
- Rising global prevalence of overweight and obesity necessitates advanced treatment strategies.
- Current lifestyle modifications yield limited weight loss (3-5%), insufficient for significant health improvements.
- Pharmacotherapy is crucial for achieving substantial weight loss (5-15%) and managing obesity comorbidities.
Purpose of the Study:
- To evaluate the efficacy and safety of retatrutide, a triple agonist, for weight loss in individuals with overweight and obesity.
- To assess the pharmacokinetic profile and tolerability of retatrutide.
- To compare retatrutide's weight loss outcomes against placebo in clinical trials.
Main Methods:
- Phase 1 and 2 clinical trials were conducted to assess retatrutide.
- Pharmacokinetics, safety, tolerability, and weight loss efficacy were evaluated in patients with obesity and/or type 2 diabetes.
- Retatrutide targets glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor, and glucagon receptor.
Main Results:
- Retatrutide demonstrated dose-proportional pharmacokinetics with a mean half-life of approximately 6 days, supporting once-weekly dosing.
- The safety profile was comparable to existing GLP-1R agonists, with gastrointestinal disorders as the most common adverse effects.
- Significant and superior weight loss was observed with retatrutide compared to placebo, with higher doses showing greater efficacy.
Conclusions:
- Retatrutide exhibits superior efficacy as a weight loss medication for individuals with overweight and obesity.
- The drug's safety and tolerability profile are promising for adjunctive obesity treatment.
- Retatrutide represents a significant advancement in pharmacotherapy for weight management.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
250
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
250
01:17Drugs for Treatment of Diarrhea-Predominant IBS
117
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
117
01:23Antidepressant Drugs: MAOIs and Other Agents
159
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
159
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
172
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
172
01:21Drugs for Treatment of Constipation-Predominant IBS
109
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
109
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
221
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
221